COMP <GO>
GRAL vs MOH // RSI-14 & 200D SMA MOMENTUM
GRAIL Inc. (NASDAQ) VS. Molina Healthcare Inc (NYSE) • 15-METRIC TALLY: GRAL 6
— MOH 5
▲ RSI-14 & 200D SMA MOMENTUM LEADER: GRAL
LAST: $133.76 (-6.74%) • MKT CAP: $6.41B
rsi-technicals
54.0
LAST: $208.45 (+1.79%) • MKT CAP: $10.69B
rsi-technicals
52.0
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (GRAL VS. MOH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | GRAL | MOH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 13.10% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -18.00% | 17.20% | -35.20 | MOH | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 11.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -4.23% | -6.12% | +1.89 | GRAL | /fcf-yield <GO> |
| Operating Margin | -60.00% | 1.70% | -61.70 | MOH | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 1.00% | -61.00 | MOH | /net-margins <GO> |
| Revenue Growth (YoY) | 17.20% | 11.70% | +5.50 | GRAL | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 7.26 | 4.34 | +2.92 | GRAL | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 4/9 | +2.00 | GRAL | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 54.0 | 52.0 | +2.00 | GRAL | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.00 | 0.94 | +0.06 | GRAL | /macro-sensitivity <GO> |
| Forward P/E Multiple | 22.0x | 20.5x | +1.50 | MOH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $6.41B | $10.69B | -$4.28B | MOH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | GRAL REV | MOH REV | GRAL GROSS % | MOH GROSS % | GRAL FCF | MOH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $147.2M | $45.43B | — | 13.1% | -$299.9M | -$636.0M |
| FY 2024 | $125.6M | $40.65B | — | 15.3% | -$582.4M | $544.0M |
| FY 2023 | $93.1M | $34.07B | — | — | -$600.0M | $128.8M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
GRAL // BETA 1.00
MOH // BETA 0.94